130 Results for "

DYRK

" in MedChemExpress (MCE) Product Catalog:
Products (130)

130 Results for "DYRK" in MCE Product Catalog:

  • Targets Recommended:
  • Recombinant Proteins Recommended:
29
29 Publications Verification
Cat. No.: HY-N0737A
CAS No.: 442-51-3
Synonyms: Telepathine
Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM .
loading...
    loading...
29
29 Publications Verification
Cat. No.: HY-N0737
CAS No.: 343-27-1
Synonyms: Telepathine hydrochloride
Harmine Hydrochloride (Telepathine Hydrochloride) is a natural DYRK inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-105309
CAS No.: 1025821-33-3
Purity:  99.77%
Target:  

DYRK

Research Areas:  

Cardiovascular Disease

GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12277
CAS No.: 1594092-37-1
Purity:  99.87%
Target:  

DYRK

Research Areas:  

Cancer

AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC50 of 17 nM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-101298
CAS No.: 57046-73-8
Purity:  99.87%
Target:  

Kinesin

Research Areas:  

Neurological Disease

Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15838
CAS No.: 147591-46-6
Purity:  99.92%
Target:  

DYRK

Research Areas:  

Cancer

ID-8 is an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK). ID-8 sustains embryonic stem cell (ESC) self-renewal and pluripotency. ID-8 enhances Wnt-mediated hESC survival and proliferation via inhibition of DYRKs .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-112296
CAS No.: 2407433-00-3
Purity:  99.64%
Target:  

CDK Apoptosis DYRK

Research Areas:  

Cancer

T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-132308
CAS No.: 2814486-79-6
Purity:  99.71%
Target:  

DYRK

Research Areas:  

Neurological Disease

DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1 inhibits DYRK1A phosphorylation activity with an IC50 value of 220 nM. DYRK1-IN-1 can be used for the research of central nervous system penetrant DYRK1A chemical probe .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108476
CAS No.: 1169755-45-6
Purity:  99.32%
Target:  

DYRK

Research Areas:  

Cancer

INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC50s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a Ki value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13455
CAS No.: 184582-62-5
Purity:  99.58%
Target:  

Haspin Kinase DYRK

Research Areas:  

Cancer

LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-111380
CAS No.: 1425945-60-3
Purity:  98.16%
Target:  

DYRK

Research Areas:  

Neurological Disease

EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis - .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117391
CAS No.: 1679330-37-0
Purity:  99.95%
Target:  

DYRK

Research Areas:  

Metabolic Disease Cancer

AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC50 of 7 nM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13455A
CAS No.: 2309172-48-1
Purity:  99.78%
Target:  

Haspin Kinase DYRK

Research Areas:  

Cancer

LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-135906
CAS No.: 1085822-09-8
Purity:  ≥99.0%
Research Areas:  

Cancer

CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-142295
CAS No.: 2561414-56-8
Purity:  98.32%
Target:  

DYRK

Research Areas:  

Metabolic Disease

GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-X0009
CAS No.: 2247481-08-7
Synonyms: GFH009; JSH-009; SLS009
Tambiciclib (GFH009, JSH-009) is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib can be used for AML research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117049
CAS No.: 1112978-84-3
Purity:  98.70%
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and CDC-like kinases (CLKs). Leucettine L41 can also inhibit GSK-3 singnaling. Leucettine L41 can inhibit cell apoptosis and ROS production. Leucettine L41 can promote β-cell cell cycle progression, cell proliferation and increase insulin secretion. Leucettine L41 can be used for the researches of neurological disease and metabolic disease, such as Alzheimer’s disease (AD) and diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-142295A
CAS No.: 2561414-57-9
Target:  

DYRK

Research Areas:  

Metabolic Disease

GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12838
CAS No.: 1386979-55-0
Purity:  99.53%
Synonyms: Mirk-IN-1; DYRK1B/A-IN-1
Target:  

DYRK

Research Areas:  

Cancer

RO5454948 (Compound 9) is the inhibitor for Dyrk1B and Dyrk1A with IC50 of 68 nM and 22 nM. RO5454948 exhibits cytotoxicity in cancer cell SW620 with EC50 of 1.9 μM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-110052
CAS No.: 934358-00-6
Purity:  99.45%
Target:  

Casein Kinase

Research Areas:  

Cancer

TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
loading...
    loading...